# Sofosbuvir + Velpatasvir

## Epclusa 400/100mg

| TAH Drug Code      | [**OEPC**](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OEPC)                                                                                                                                                                                                                                                                                                                                                                                          |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of adult chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infections.                                                                                                                                                                                                                                                                                                                                                                        |
| Dosing             | One tablet contains sofosbuvir 400 mg/velpatasvir 100 mg. One tablet once daily for 12 weeks.                                                                                                                                                                                                                                                                                                                                                                     |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Contraindications  | Hypersensitivity to sofosbuvir, velpatasvir, or any component of the formulation. If sofosbuvir/velpatasvir is administered with ribavirin, the contraindications to ribavirin also apply. See ribavirin manufacturer's labeling information.                                                                                                                                                                                                                     |
| Adverse Effects    | >10%: Central nervous system: Headache (22%), fatigue (15%) 1% to 10%: Central nervous system: Irritability (?5%), insomnia (5%), depression (1%) Dermatologic: Skin rash (2%) Gastrointestinal: Nausea (9%), increased serum lipase (>3X ULN: 3% to 6%) Neuromuscular & skeletal: Weakness (5%), increased creatine phosphokinase (?10X ULN: 1% to 2%) Frequency not defined: Infection: Reactivation of HBV <1%: postmarketing, and/or case reports: Angioedema |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

